Anavex Life Sciences Corp. Acquires a Portfolio of Patents and Appoints Dr. Alexandre Vamvakides as CSO and Director

Geneva, Switzerland — January 31, 2007 — Anavex Life Sciences Corp. (OTCBB: AVXL) (the “Company”) announces that it has acquired a portfolio of three patents and one patent application covering drug candidates indented to be further developed through commercialization targeting the areas of neurological diseases and cancer. The patents were assigned by Dr. Alexandre Vamvakides,…

OUR TEAM

OUR TEAM Management Christopher U. Missling, MS, PhD, MBA Dr. Missling, President and CEO of Anavex, has over 20 years of healthcare industry experience within large pharmaceutical companies, the biotech industry and investment banking. Prior to joining Anavex®, he served as the Chief Financial Officer of Curis and ImmunoGen. In addition, at Aventis (now Sanofi), …

Anavex Strengthens Board of Directors

NEW YORK, NY – June 18, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced the appointment of Steffen Thomas, PhD, to its Board of Directors. Dr.…

Anavex Awarded New U.S. Patent

New York — June 4, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS) and various types of cancer, is pleased to announce that it has been issued U.S. Patent No. 8,673,931…

Anavex Strengthens Alzheimer’s Pipeline, Obtains Exclusive Worldwide Rights to Intellectual Property

Preclinical Data Presented at 13th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy New York, NY — March 31, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s, diseases of the central nervous system (CNS) and various types of cancer,…

Anavex Retains Novak Druce Connolly Bove & Quigg to Maximize Value of Intellectual Property Portfolio

Vancouver, BC — February 4, 2013 — Anavex Life Sciences Corp. (“Anavex”) (OTCQB: AVXL) is pleased to announce that it has retained specialized intellectual property law firm Novak Druce Connolly Bove & Quigg LLP (“Novak Druce”) to assist in maximizing the value of the company’s intellectual property (IP) portfolio.  One of the largest IP boutique…